

MATRIX

7 July 2011

MATRIX CONTINUES CORPORATE GAINS

Appointed Nominated Adviser and Broker to Proximagen Group plc

Matrix Group's investment banking business has today been appointed as Nominated Adviser and Broker to Proximagen Group plc (AIM: PRX), the rapidly growing company with a principal focus on the treatment of disorders of the central nervous system, with immediate effect.

David Wilson, Deputy CEO of the investment banking business of Matrix Group, commented:

"Matrix is delighted to have won the role of Nominated Adviser and Broker to Proximagen Group. This appointment underlines our strengthened capabilities and commitment to become the leading Healthcare investment banking practice in Europe. Furthermore, it also emphasises the strength and credentials of our integrated Healthcare team, which has a unique combination of strong relationships, influential distribution, sector specific corporate finance and research expertise."

For further information please contact:

Kreab Gavin Anderson

James Benjamin / Madeleine Palmstierna + 44 (0) 20 7074 1800

Matrix Group

Natasha Newman +44 (0) 20 3206 7130

Notes to Editors

Matrix Group's Investment Banking business conducts business through Matrix Corporate Capital LLP ("Matrix"). Matrix is a client focused, advisory, capital raising and securities sales, trading and research firm in the small and mid-cap UK and pan-European space. It brings together considerable experience, knowledge and access to meet and match the strategic ambitions of growing companies and the performance needs of investing institutions. Today Matrix has a 100 strong investment banking team advising over 80 retained clients and serving the sales, trading and research needs of more than 200 institutional customers.

Matrix has significantly increased research coverage and their team of 25 analysts now covers around 200 stocks across small, mid and large cap in these selected, focused sectors:

- Business Services & Industrial Growth
- Consumer Goods & Services
- Healthcare
- Investment Funds
- Real Estate
- Resources, Energy & Clean Tech
- Technology, Media & Telecom

The Investment Banking business is part of Matrix Group, a privately owned financial services business in the UK with around £4.25 billion of assets under management and around 250 professionals employed across three divisions: Asset Management, Investment Banking and Property. Since inception in 1987, Matrix has raised over £20 billion of assets for investments across these business areas.

Proximagen Group plc

Proximagen Group plc (AIM: PRX) is focused on the development and commercialisation of novel therapeutics primarily for diseases of the central nervous system. The Company is developing a broad pipeline of drug candidate programmes and has plans for substantial future growth through a strategy of acquisition and consolidation of innovative drug candidate programmes in its core disease areas. Proximagen believes that significant value creation opportunities can arise by building critical mass, reducing the cost base, and focusing resources on a more promising pipeline where tough decisions will be taken to discontinue weak programmes.

Proximagen strives for true scientific innovations that break new ground in treatment. Using this standard as a development benchmark makes things more challenging, but demonstrates the Company's commitment to pursuing only those opportunities that improve upon current therapies in meaningful ways and represent the best chance of generating significant commercial value.

For more information, please visit the Company's website at www.proximagen.com.